Coronary stenting with MGuard: First-in-man trial

Medicine and Dentistry

• Vein Graft 100%
• Percutaneous Coronary Intervention 100%
• Coronary Stenting 100%
• Phosphotransferase 66%
• Creatinine 66%
• Major Adverse Cardiac Event 66%
• Coronary Vein 66%
• Embolization 33%
• Coronary Artery 33%
• Myocardial Infarction 33%
• Heparin 33%
• Coronary Artery Bypass Graft 33%
• Acetylsalicylic Acid 33%
• Heart Death 33%
• Target Lesion Revascularization 33%
• Stent Thrombosis 33%
• Glycoprotein IIb/IIIa Inhibitors 33%
• Bivalirudin 33%
• Troponin 33%
• Clopidogrel 33%
• Electrocardiography 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Phosphotransferase 100%
• Creatinine 100%
• Major Adverse Cardiac Event 100%
• Clopidogrel 50%
• Heart Infarction 50%
• Acetylsalicylic Acid 50%
• Heart Death 50%
• Heparin 50%
• Troponin 50%
• Stent Thrombosis 50%
• Fibrinogen Receptor 50%
• Bivalirudin 50%